...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
【24h】

Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.

机译：每周一次大剂量立体定向身体放射治疗肺癌：对60例早期，42例局部晚期和7例转移性肺癌进行6年分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To explore once-weekly stereotactic body radiotherapy (SBRT) in nonoperable patients with localized, locally advanced, or metastatic lung cancer. METHODS AND MATERIALS: A total of 102 primary (89 untreated plus 13 recurrent) and 7 metastatic tumors were studied. The median follow-up was 38 months, the average patient age was 75 years. Of the 109 tumors studied, 60 were Stage I (45 IA and 15 IB), 9 were Stage II, 30 were Stage III, 3 were Stage IV, and 7 were metastases. SBRT only was given in 73% (40 Gy in four fractions to the planning target volume to a total dose of 53 Gy to the isocenter for a biologically effective dose of 120 Gy(10)). SBRT was given as a boost in 27% (22.5 Gy in three fractions once weekly for a dose of 32 Gy at the isocenter) after 45 Gy in 25 fractions to the primary plus the mediastinum. The total biologically effective dose was 120 Gy(10). Respiration gating was used in 46%. RESULTS: The overall response rate was 75%; 33% had a complete response. The overall responserate was 89% for Stage IA patients (40% had a complete response). The local control rate was 82%; it was 100% and 93% for Stage IA and IB patients, respectively. The failure rate was 37%, with 17% within the planning target volume. No Grade 3-4 acute toxicities developed in any patient; 12% and 7% of patients developed Grade 1 and 2 toxicities, respectively. Late toxicity, all Grade 2, developed in 3% of patients. The 5-year cause-specific survival rate for Stage I was 70% and was 74% and 64% for Stage IA and IB patients, respectively. The 3-year Stage III cause-specific survival rate was 30%. The patients with metastatic lung cancer had a 57% response rate, a 27% complete response rate, an 86% local control rate, a median survival time of 19 months, and 23% 3-year survival rate. CONCLUSIONS: SBRT is noninvasive, convenient, fast, and economically attractive; it achieves results similar to surgery for early or metastatic lung cancer patients who are older, debilitated, and with comorbidities. Elderly patientsand/or patients medically unfit for combined modality therapy with locally advanced disease can find an effective palliative alternative in SBRT.
机译：目的：探讨针对局部，局部晚期或转移性肺癌的不可手术患者每周一次的立体定向放射治疗（SBRT）。方法和材料：共研究了102例原发性肿瘤（89例未经治疗加13例复发）和7例转移性肿瘤。中位随访时间为38个月，平均患者年龄为75岁。在研究的109种肿瘤中，有60种为I期（45 IA和15 IB），II期为9种，III期为30种，IV期为3种，转移为7种。仅以73％的比例给予SBRT（以40 Gy的比例分配至计划目标体积，以等剂量的总剂量53 Gy给予等中心点，从而获得120 Gy的生物学有效剂量（10））。 SBRT增加25％至45 Gy至原发加纵隔后，增加27％（每周3次，在等中心点为32 Gy，每周三部分为22.5 Gy）。总的生物有效剂量为120 Gy（10）。呼吸门控的使用率为46％。结果：总有效率75％。 33％的人有完整的回应。 IA期患者的总缓解率为89％（40％完全缓解）。地方控制率为82％; IA和IB期患者分别为100％和93％。失败率为37％，计划目标范围内为17％。任何患者均未发生3-4级急性毒性;分别有12％和7％的患者出现1级和2级毒性。 2％的晚期毒性均为3％的患者。 I期的5年病因特异性生存率分别为70％，IA和IB期患者分别为74％和64％。 3年期III期特定病因生存率为30％。转移性肺癌患者的缓解率为57％，完全缓解率为27％，局部控制率为86％，中位生存时间为19个月，三年生存率为23％。结论：SBRT无创，方便，快速且在经济上具有吸引力。对于年龄较大，虚弱且有合并症的早期或转移性肺癌患者，它可获得与手术相似的结果。老年患者和/或在医学上不适合与局部晚期疾病联合治疗的患者可以在SBRT中找到有效的姑息替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号